Феохромоцитома і парагангліома. Клінічні настанови Ендокринологічного товариства. Частина 3

Agarwal G., Sadacharan D., Aggarwal V. et al. Surgical management of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series // Langenbecks Arch. Surg. — 2012. — 397. — P. 1109—1116.

Alesina P.F., Hinrichs J., Meier B. et al. Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas // Langenbecks Arch. Surg. — 2012. — 397. — P. 233—238.

Amar L., Bertherat J., Baudin E. et al. Genetic testing in pheo­chromocytoma or functional paraganglioma // J. Clin. Oncol. — 2005. — 23. — P. 8812—8818.

Amar L., Fassnacht M., Gimenez-Roqueplo A.P. et al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma // Horm. Metab. Res. — 2012. — 44. — P. 385—389.

Asari R., Scheuba C., Kaczirek K., Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A // Arch. Surg. — 2006. — 141. — P. 1199—1205.

Baez J.C., Jagannathan J.P., Krajewski K. et al. Pheochromocytoma and paraganglioma: imaging characteristics // Cancer Imaging. — 2012. — 12. — P. 153—162.

Benhammou J.N., Boris R.S., Pacak K. et al. Functional and oncologic outcomes of partial adrenalectomy for pheochro­mo­cytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup // J. Urol. — 2010. — 184. — P. 1855—1859.

Benn D.E., Gimenez-Roqueplo A.P., Reilly J.R. et al. Clinical presentation and penetrance of pheochromocytoma/paragan­glioma syndromes // J. Clin. Endocrinol. Metab. — 2006. — 91. — P. 827—836.

Bergamini C., Martellucci J., Tozzi F., Valeri A. Complications in laparoscopic adrenalectomy: the value of experience // Surg. Endosc. — 2011. — 25. — P. 3845—3851.

Brauckhoff M., Gimm O., Thanh P.N. et al. Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy // Surgery. — 2003. — 134. — P. 1020—1027.

Bravo E.L. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma // Endocr. Rev. — 1994. — 15. — P. 356—368.

Briggs R.S., Birtwell A.J., Pohl J.E. Hypertensive response to labetalol in phaeochromocytoma // Lancet. — 1978. — 1. — P. 1045—1046.

Brunaud L., Ayav A., Zarnegar R. et al. Prospective evaluation of 100 robotic-assisted unilateral adrenalectomies // Surgery. — 2008. — 144. — P. 995—1001.

Burnichon N., Rohmer V., Amar L. et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas // J. Clin. Endocrinol. Metab. — 2009. — 94. — P. 2817—2827.

Chew S.L. Recent developments in the therapy of phaeochromocy­toma // Expert Opin. Investig. Drugs. — 2004. — 13. — P. 1579—1583.

Combemale F., Carnaille B., Tavernier B. et al. Exclusive use of calcium channel blockers and cardioselective-blockers in the preand per-operative management of pheochromocytomas. 70 cases [in French] // Ann. Chir. — 1998. — 52. — P. 341—345.

Dickson P.V., Alex G.C., Grubbs E.G. et al. Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma // Surgery. — 2011. — 150. — P. 452—458.

Eisenhofer G., Huynh T.T., Elkahloun A. et al. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma // Am. J. Physiol. Endocrinol. Metab. — 2008. — 295. — P. E1223—E1233.

Eisenhofer G., Huynh T.T., Hiroi M., Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma // Rev. Endocr. Metab. Disord. — 2001. — 2. — P. 297—311.

Eisenhofer G., Lenders J.W., Siegert G. et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and para­ganglioma in relation to established risk factors of tumour size, location and SDHB mutation status // Eur. J. Cancer. — 2012. — 48. — P. 1739—1749.

Eisenhofer G., Lenders J.W., Timmers H. et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma // Clin. Chem. — 2011. — 57. — P. 411—420.

Eisenhofer G., Pacak K., Huynh T.T. et al. Catecholamine meta­bolomics and secretory phenotypes in phaeochromocytoma // Endocr. Relat. Cancer. — 2011. — 18. — P. 97—111.

Eisenhofer G., Timmers H.J., Lenders J.W. et al. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location // J. Clin. Endocrinol. Metab. — 2011. — 96. — P. 375—384.

Eisenhofer G., Tischler A.S., de Krijger R.R. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paragan­glioma: from routine laboratory methods to disease stratification // Endocr. Pathol. — 2012. — 23. — P. 4—14.

Eisenhofer G., Walther M.M., Huynh T.T. et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes // J. Clin. Endocrinol. Metab. — 2001. — 86. — P. 1999—2008.

Gagner M., Breton G., Pharand D., Pomp A. Is laparoscopic adrenalectomy indicated for pheochromocytomas? // Surgery. — 1996. — 120. — P. 1076—1079.

Gallagher S.F., Wahi M., Haines K.L. et al. Trends in adrenalectomy rates, indications, and physician volume: a statewide analysis of 1816 adrenalectomies // Surgery. — 2007. — 142. — P. 1011—1021.

Gimenez-Roqueplo A.P., Caumont-Prim A., Houzard C. et al. Imaging work-up for screening of paraganglioma and pheochro­mocytoma in SDH mutation carriers: a multicenter prospective study from the PGL.EVA investigators // J. Clin. Endocrinol. Metab. — 2013. — 98. — P. E162—E173.

Gimenez-Roqueplo A.P., Favier J., Rustin P. et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas // Cancer Res. — 2003. — 63. — P. 5615—5621.

Goers T.A., Abdo M., Moley J.F. et al. Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the lapa­roscopic era: a comparison with adrenal pheochromocytoma // Surg. Endosc. — 2013. — 27. — P. 428—433.

Goldstein R.E., O’Neill J.A.Jr., Holcomb G.W. 3rd et al. Clinical experience over 48 years with pheochromocytoma // Ann. Surg. — 1999. — 229. — P. 755—764.

Grosse H., Schrцder D., Schober O. et al. The importance of high-dose-receptor blockade for blood volume and hemodynamics in pheochromocytoma [in German] // Anaesthesist. — 1990. — 39. — P. 313—318.

Grubbs E.G., Rich T.A., Ng C. et al. Long-term outcomes of surgical treatment for hereditary pheochromocytoma // J. Am. Coll. Surg. — 2013. — 216. — P. 280—289.

Hernandez-Boussard T., McDonald K.M., Morton J.M. et al. Determinants of adverse events in vascular surgery // J. Am. Coll. Surg. — 2012. — 214. — P. 788—797.

Hoegerle S., Ghanem N., Altehoefer C. et al. 18F-DOPA positron emission tomography for the detection of glomus tumours // Eur. J. Nucl. Med. Mol. Imaging. — 2003. — 30. — P. 689—694.

Hoffman B.B. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists / Hardman J.G., Limbird L.E., eds. Goodman & Gillman’s The Pharmacological Basis of Therapeutics. — Philadelphia; McGraw-Hill; 2001. — P. 215—268.

Iihara M., Suzuki R., Kawamata A. et al. Adrenal-preserving laparoscopic surgery in selected patients with bilateral adrenal tumors // Surgery. — 2003. — 134. — P. 1066—1072.

Ilias I., Chen C.C., Carrasquillo J.A. et al. Comparison of 6—18Ffluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma // J. Nucl. Med. — 2008. — 49. — P. 1613—1619.

Jankovic R.J., Konstantinovic S.M., Milic D.J. et al Can a patient be successfully prepared for pheochromocytoma surgery in three days? // A case report. Minerva Anestesiol. — 2007. — 73. — P. 245—248.

Kaye D.R., Storey B.B., Pacak K. et al. Partial adrenalectomy: underused first line therapy for small adrenal tumors // J. Urol. — 2010. — 184. — P. 18—25.

King K.S., Chen C.C., Alexopoulos D.K. et al. Functional imaging of SDH-related head and neck paragangliomas: comparison of 18Fflu­o­­ro­dihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy // J. Clin. Endocrinol. Metab. — 2011. — 96. — P. 2779—2785.

Kinney M.A., Narr B.J., Warner M.A. Perioperative management of pheochromocytoma // J. Cardiothorac. Vasc. Anesth. — 2002. — 16. — P. 359—369.

Kocak S., Aydintug S., Canakci N. Alpha blockade in preoperative preparation of patients with pheochromocytomas // Int. Surg. — 2002. — 87. — P. 191—194.

Korevaar T.I., Grossman A.B. Pheochromocytomas and para­gangliomas: assessment of malignant potential // Endocrine. — 2011. — 40. — P. 354—365.

Lebuffe G., Dosseh E.D., Tek G. et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeo­chromocytomas and paragangliomas // Anaesthesia. — 2005. — 60. — P. 439—444.

Lentschener C., Gaujoux S., Tesniere A., Dousset B. Point of controversy: perioperative care of patients undergoing pheo­chromocytoma removal-time for a reappraisal? // Eur. J. Endo­crinol. — 2011. — 165. — P. 365—373.

Li M.L., Fitzgerald P.A., Price D.C., Norton J.A. Iatrogenic pheochromocytomatosis: a previously unreported result of lapa­roscopic adrenalectomy // Surgery. — 2001. — 130. — P. 1072—1077.

Machens A., Brauckhoff M., Gimm O., Dralle H. Risk-oriented approach to hereditary adrenal pheochromocytoma // Ann NY Acad. Sci. — 2006. — 1073. — P. 417—428.

Malchoff C.D., MacGillivray D., Shichman S. Pheochromocytoma treatment / Mansoor G.A., ed. Secondary Hypertension. — Totowa, NJ: Humana Press, 2004. — P. 235—249.

Mannelli M. Management and treatment of pheochromocytomas and paragangliomas // Ann. NY Acad. Sci. — 2006. — 1073. — P. 405—416.

Melmed S., Polonsky K.S., Reed Larsen P., Kronenberg H.M. Williams Textbook of Endocrinology. 12th ed. — Philadelphia, PA: Elsevier; 2011.

Neumann H.P., Pawlu C., Peczkowska M. et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations // JAMA. — 2004. — 292. — P. 943—951.

Opocher G., Schiavi F. Functional consequences of succinate dehydrogenase mutations // Endocr. Pract. — 2011. — 17 (Suppl. 3). — P. 64—71.

Pacak K. Preoperative management of the pheochromocytoma patient // J. Clin. Endocrinol. Metab. — 2007. — 92. — P. 4069—4079.

Park H.S., Roman S.A., Sosa J.A. Outcomes from 3144 adre­na­lectodoimies in the United States: which matters more, surgeon volume or specialty? // Arch. Surg. — 2009. — 144. — P. 1060—1067.

Peitzsch M., Prejbisz A., Kroiss M. et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraper­formance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma // Ann. Clin. Biochem. — 2013. — 50. — P. 147—155.

Perry L.B., Gould A.B.Jr. The anesthetic management of pheochromocytoma effect of preoperative adrenergic blocking drugs // Anesth. Analg. — 1972. — 51. — P. 36—40.

Perry R.R., Keiser H.R., Norton J.A. et al. Surgical management of pheochromocytoma with the use of metyrosine // Ann. Surg. — 1990. — 212:621—628.

Plouin P.F., Duclos J.M., Soppelsa F. et al. Factors associated with perioperative morbidity and mortality in patients with pheoch­romocytoma: analysis of 165 operations at a single center // J. Clin. Endocrinol. Metab. — 2001. — 86. — P. 1480—1486.

Plouin P.F., Fitzgerald P., Rich T. et al. Metastatic pheochromocytoma and paraganglioma:focus on therapeutics // Horm. Metab. Res. — 2012. — 44. — P. 390—399.

Prys-Roberts C., Farndon J.R. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma // World J. Surg. — 2002. — 26. — P. 1037—1042.

Ross E.J., Prichard B.N., Kaufman L. et al. Preoperative and operative management of patients with phaeochromocytoma // Br. Med. J. — 1967. — 1. — P. 191—198.

Sanford T.H., Storey B.B., Linehan W.M. et al. Outcomes and timing for intervention of partial adrenalectomy in patients with a solitary adrenal remnant and history of bilateral phaeochromocytomas // BJU Int. — 2011. — 107. — P. 571—575.

Scholten A., Cisco R.M., Vriens M.R. et al. Pheochromocytoma crisis is not a surgical emergency // J. Clin. Endocrinol. Metab. — 2013. — 98. — P. 581— 591.

Shah U., Giubellino A., Pacak K. Pheochromocytoma: implications in tumorigenesis and the actual management // Minerva Endocrinol. — 2012. — 37. — P. 141—156.

Shao Y., Chen R., Shen Z.J. et al. Preoperative-blockade for normotensive pheochromocytoma: is it necessary? // J. Hypertens. — 2011. — 29. — P. 2429—2432.

Shen W.T., Grogan R., Vriens M. et al. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy // Arch. Surg. — 2010. — 145. — P. 893—897.

Srirangalingam U., Khoo B., Walker L. et al. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours // Endocr. Relat. Cancer. — 2009. — 16. — P. 515—525.

Steinsapir J., Carr A.A., Prisant L.M., Bransome E.D.Jr. Metyrosine and pheochromocytoma // Arch. Intern. Med. — 1997. — 157. — P. 901—906.

Timmers H.J., Chen C.C., Carrasquillo J.A. et al. Comparison of 18F- fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochro­mocytoma and paraganglioma // J. Clin. Endocrinol. Metab. — 2009. — 94. — P. 4757—4767.

Timmers H.J., Gimenez-Roqueplo A.P., Mannelli M., Pacak K. Clinical aspects of SDH-related pheochromocytoma and paragan­glioma // Endocr. Relat. Cancer. — 2009. — 16. — P. 391—400.

Timmers H.J., Kozupa A., Eisenhofer G. et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas // J. Clin. Endocrinol. Metab. — 2007. — 92. — P. 779—786.

Timmers H.J., Taieb D., Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and para­ganglioma // Horm. Metab. Res. — 2012. — 44. — P. 367—372.

Ulchaker J.C., Goldfarb D.A., Bravo E.L., Novick A.C. Successful outcomes in pheochromocytoma surgery in the modern era // J. Urol. — 1999. — 161. — P. 764—767.

Villar J.M., Moreno P., Ortega J. et al. Results of adrenal surgery. Data of a Spanish National Survey // Langenbecks Arch. Surg. — 2010. — 395. — P. 837—843.

Volkin D., Yerram N., Ahmed F. et al. Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome // J. Pediatr. Surg. — 2012. — 47. — P. 2077—2082.

Walz M.K., Alesina P.F., Wenger F.A. et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retro­peritoneal paragangliomas: results of 161 tumors in 126 patients // World J. Surg. — 2006. — 30. — P. 899—908.

Weingarten T.N., Cata J.P., O’Hara J.F. et al. Comparison of two preoperative medical management strategies for laparoscopic rese­ction of pheochromocytoma // Urology. — 2010. — 76. — P. 508.e6—e11.

Welander J., Sцderkvist P., Gimm O. Genetics and clinical charac­teristics of hereditary pheochromocytomas and paragangliomas // Endocr. Relat. Cancer. — 2011. — 18. — P. R253—R276.

Williams D.T., Dann S., Wheeler M.H. Phaeochromocytoma-views on current management // Eur. J. Surg. Oncol. — 2003. — 29. — P. 483—490.

Wouters M.W., Gooiker G.A., van Sandick J.W., Tollenaar R.A. The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis // Cancer. — 2012. — 118. — P. 1754—1763.

Wдngberg B., Muth A., Khorram-Manesh A. et al. Malignant pheochromocytoma in a population-based study: survival and clinical results // Ann. NY Acad. Sci. — 2006. — 1073. — P. 512—516.

Young W.F.Jr. Pheochromocytoma: 1926—1993 // Trends Endocrinol. Metab. — 1993. — 4. — P. 122—127.